THERAPY DUAL 8 CARDIAC ABLATION SYSTEM,THERAM 8MM THERMISTER ABLATION CATHETER SAFIRE TX ABLATION CATHETER
Irvine Biomedical,Inc.(Ibi) · Decision date Nov 18, 2005
What did the FDA approve?
FDA records P040042 as an original PMA application. The recorded decision is approval, dated Nov 18, 2005.
FDA approval order statement
APPROVAL FOR THE THERAPY DUAL 8 CARDIAC ABLATION SYSTEM. THE DEVICE IS INDICATED FOR THE TREATMENT OF TYPICAL ATRIAL FLUTTER.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 18, 2005
Regulatory record facts
- Identifier
- P040042
- Regulatory pathway
- Premarket approval application
- Applicant
- Irvine Biomedical,Inc.(Ibi)
- Product code
- OAD
- Decision code
- APPR
- Decision date
- Nov 18, 2005
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.
- Applicant
- Irvine Biomedical,Inc.(Ibi)
- Product code
- OAD
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P040042 received
Application receipt date recorded by FDA.
P040042 · FDA decision
APPR
P040042/S060 · Related supplement
Therapy Dual-8 Ablation Catheter
Timeline entries are records held by MedtechLedger for P040042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Therapy Dual-8 Ablation CatheterP040042/S060 | Irvine Biomedical,Inc.(Ibi) | PMA supplement | Sep 3, 2026 | FDA |
Explore the linked device profile
Other records with product code OAD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
THERMOCOOL SMARTTOUCH SF CatheterP030031/S142 | Biosense Webster, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| Biosense Webster, Inc. | PMA approval | Nov 5, 2004 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Irvine Biomedical,Inc.(Ibi)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2375 Morse Ave., Irvine, CA, 92614
Sources and methodology
- Original FDA record: P040042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records